| Authors (Year) | Study type | Selection | Comparability | Outcome | Final score |
|---------------|------------|-----------|---------------|---------|-------------|
|               |            | Representativeness of the exposed cohort | Comparability of cohorts on the basis of the design or analysis | Adequacy of follow up of cohorts | score |
|               |            | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Assessment of outcome | Was follow-up long enough for outcomes to occur | |
| Le Hou 2020   | Cohort     | *          |   |   |   |   |   | 9 |
| Haghikia A 2019 | Cohort     | *          |   |   |   |   |   | 9 |
| Zhai Q 2019   | Cohort     | *          |   |   |   |   |   | 4 |

a, Western Norway Coronary Angiography Cohort (WECAC) b, Hordaland Health Study (HUSK) cohort, c, first pilot cohort; d, Prospective Cohort With Incident Stroke (PCWIS)9
### Table S2. Agency for Healthcare Research and Quality (AHRQ) checklist to assess quality of the cross-sectional studies

| ARHQ Methodology Checklist items for Cross-Sectional study | Wu C et al | Zhu C et al | Yin J et al | Rexidamu M et al | Nie J et al | Liang Z et al |
|----------------------------------------------------------|-----------|------------|-------------|------------------|------------|--------------|
| 1) Define the source of information (survey, record review) | ✗         | ✗          | ✗           | ✗                | ✗          | ✗            |
| 2) List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications | ✗         | ✗          | ✗           | ✗                | ✗          | ✗            |
| 3) Indicate time period used for identifying patients | ✗         | ✗          | ✗           | ✗                | ✗          | ✗            |
| 4) Indicate whether or not subjects were consecutive if not population-based | U         | U          | U           | U                | U          | U            |
| 5) Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants | U         | U          | U           | U                | U          | U            |
| 6) Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements) | ✗         | ✗          | –           | ✗                | ✗          | U            |
| 7) Explain any patient exclusions from analysis | ✗         | –          | ✗           | –                | ✗          | ✗            |
| 8) Describe how confounding was assessed and/or controlled. | ✗         | ✗          | ✗           | ✗                | ✗          | ✗            |
| 9) If applicable, explain how missing data were handled in the analysis | ✗         | ✗          | U           | –                | U          | ✗            |
| 10) Summarize patient response rates and completeness of data collection | ✗         | –          | ✗           | –                | ✗          | ✗            |
| 11) Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained | –         | –          | U           | ✗                | U          | ✗            |